Literature DB >> 19536024

Cost analysis with censored data.

Yijian Huang1.   

Abstract

Economic evaluation of medical interventions has become an accepted, and often required, adjunct to the standard effectiveness and safety assessment in clinical research. However, the statistical analysis can be challenging due to censored cost data, as commonly obtained in medical studies. Over the past decade, important statistical issues that arise from censored cost data have been identified and a number of advances made to tackle them. In this article, we will describe these issues, including induced dependent censoring and limited identifiability with the cost distribution, and review recent statistical developments. Available methods address either time-restricted medical cost or lifetime medical cost jointly with survival time. Their applicability and limitation in various practical situations will be discussed.

Entities:  

Mesh:

Year:  2009        PMID: 19536024      PMCID: PMC2748913          DOI: 10.1097/MLR.0b013e31819bc08a

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  11 in total

1.  On estimating medical cost and incremental cost-effectiveness ratios with censored data.

Authors:  H Zhao; L Tian
Journal:  Biometrics       Date:  2001-12       Impact factor: 2.571

Review 2.  The burden of illness of cancer: economic cost and quality of life.

Authors:  M L Brown; J Lipscomb; C Snyder
Journal:  Annu Rev Public Health       Date:  2001       Impact factor: 21.981

3.  Linear regression analysis of censored medical costs.

Authors:  D Y Lin
Journal:  Biostatistics       Date:  2000-03       Impact factor: 5.899

4.  Median regression with censored cost data.

Authors:  Heejung Bang; Anastasios A Tsiatis
Journal:  Biometrics       Date:  2002-09       Impact factor: 2.571

5.  Medical cost analysis: application to colorectal cancer data from the SEER Medicare database.

Authors:  Heejung Bang
Journal:  Contemp Clin Trials       Date:  2005-10       Impact factor: 2.226

6.  On the equivalence of some medical cost estimators with censored data.

Authors:  Hongwei Zhao; Heejung Bang; Hongkun Wang; Phillip E Pfeifer
Journal:  Stat Med       Date:  2007-10-30       Impact factor: 2.373

7.  Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.

Authors:  K Kelly; J Crowley; P A Bunn; C A Presant; P K Grevstad; C M Moinpour; S D Ramsey; A J Wozniak; G R Weiss; D F Moore; V K Israel; R B Livingston; D R Gandara
Journal:  J Clin Oncol       Date:  2001-07-01       Impact factor: 44.544

8.  Estimating medical costs from incomplete follow-up data.

Authors:  D Y Lin; E J Feuer; R Etzioni; Y Wax
Journal:  Biometrics       Date:  1997-06       Impact factor: 2.571

9.  The analysis of censored treatment cost data in economic evaluation.

Authors:  P Fenn; A McGuire; V Phillips; M Backhouse; D Jones
Journal:  Med Care       Date:  1995-08       Impact factor: 2.983

10.  Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer.

Authors:  Scott D Ramsey; Carol M Moinpour; Laura C Lovato; John J Crowley; Patra Grevstad; Cary A Presant; Saul E Rivkin; Karen Kelly; David R Gandara
Journal:  J Natl Cancer Inst       Date:  2002-02-20       Impact factor: 13.506

View more
  24 in total

Review 1.  The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs.

Authors:  Scott D Grosse; Richard E Nelson; Kwame A Nyarko; Lisa C Richardson; Gary E Raskob
Journal:  Thromb Res       Date:  2015-11-24       Impact factor: 3.944

2.  Cost-of-illness studies: a guide to critical evaluation.

Authors:  Allison Larg; John R Moss
Journal:  Pharmacoeconomics       Date:  2011-08       Impact factor: 4.981

3.  Nonparametric inference for median costs with censored data.

Authors:  Hongwei Zhao; Chen Zuo; Shuai Chen; Heejung Bang
Journal:  Biometrics       Date:  2012-02-24       Impact factor: 2.571

4.  Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity.

Authors:  Vasileios Fragoulakis; Rossana Roncato; Chiara Dalle Fratte; Fabrizio Ecca; Marina Bartsakoulia; Federico Innocenti; Giuseppe Toffoli; Erika Cecchin; George P Patrinos; Christina Mitropoulou
Journal:  Am J Hum Genet       Date:  2019-05-30       Impact factor: 11.025

5.  Cost-effectiveness analysis: a proposal of new reporting standards in statistical analysis.

Authors:  Heejung Bang; Hongwei Zhao
Journal:  J Biopharm Stat       Date:  2014       Impact factor: 1.051

6.  Nonparametric inference for the joint distribution of recurrent marked variables and recurrent survival time.

Authors:  Laura M Yee; Kwun Chuen Gary Chan
Journal:  Lifetime Data Anal       Date:  2015-09-30       Impact factor: 1.588

7.  Nonparametric inference for time-dependent incremental cost-effectiveness ratios.

Authors:  Laura M Yee; Kwun Chuen Gary Chan
Journal:  Stat Med       Date:  2015-07-27       Impact factor: 2.373

8.  Overview of methods to estimate the medical costs of cancer.

Authors:  William E Barlow
Journal:  Med Care       Date:  2009-07       Impact factor: 2.983

9.  Inventory of data sources for estimating health care costs in the United States.

Authors:  Jennifer L Lund; K Robin Yabroff; Yoko Ibuka; Louise B Russell; Paul G Barnett; Joseph Lipscomb; William F Lawrence; Martin L Brown
Journal:  Med Care       Date:  2009-07       Impact factor: 2.983

10.  Costs of cervical cancer treatment: population-based estimates from Ontario.

Authors:  C Pendrith; A Thind; G S Zaric; S Sarma
Journal:  Curr Oncol       Date:  2016-04-13       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.